September 20, 2019
September 20, 2019 —
Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego researchers describe new use of leukemia drug, nilotinib, to treat subtype of medulloblastoma, a deadly pediatric brain cancer.
September 5, 2019
September 5, 2019 —
The San Diego Center for AIDS Research (CFAR) at University of California San Diego has been awarded planning grants to help the federal government achieve its goal of reducing the number of new HIV infections in the United States by 90 percent by 2030.
September 3, 2019
September 3, 2019 —
A new University of California San Diego School of Medicine study links changes in the gene for the protein focal adhesion kinase, or FAK, to ovarian cancer’s ability to survive chemotherapy.
August 21, 2019
August 21, 2019 —
University of California San Diego School of Medicine researchers identified a new therapeutic approach in mouse models that halts drug resistance and cancer progression by using an antibody that induces the immune system via macrophages to seek and kill cancer cells.
August 13, 2019
August 13, 2019 —
UC San Diego School of Medicine has been awarded $9 million to fund research projects using human pluripotent stem cells, CRISPR and human organoids to dissect beta cell defects and create a human cell model of type 1 diabetes aimed at identifying the cellular actions leading to disease onset.
May 6, 2019
May 6, 2019 —
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.
April 22, 2019
April 22, 2019 —
University of California San Diego School of Medicine researchers found that treating patients with personalized precision medicine that combined therapies to target multiple alterations improved outcomes in patients with therapy resistant cancers.
April 1, 2019
April 1, 2019 —
Moores Cancer Center at UC San Diego Health treats the first patient treated for cancer with a human-induced pluripotent stem cell (iPSC)-derived cell therapy called FT500. Dan Kaufman collaborated with Fate Therapeutics to bring the iPSC-derived natural killer cell cancer immunotherapy to patients.
March 13, 2019
March 13, 2019 —
New preclinical data from University of California San Diego School of Medicine and Moores Cancer Center offers proof-of-principle for a combination immunotherapy that suppresses tumor growth in the liver. Current therapies for liver cancer are largely ineffective, resulting in poor outcomes.
February 5, 2019
February 5, 2019 —
To make it easier for patients to receive world-class cancer care, UC San Diego Health has added a new multidisciplinary cancer clinic in Hillcrest and expanded its infusion center for both oncology patients and others in need of infusion services.
